Evidence map›Paper›PMID 34329603›Full record

ArticleThe Annals of thoracic surgery2022

The Impact of Extended Delayed Surgery for Indolent Lung Cancer or Part-Solid Ground Glass Nodules.

Nicholas R Mayne, Holly Elser, Belle K Lin, Vignesh Raman, Douglas Liou, Xiao Li, Thomas A D'Amico, Chi-Fu Jeffrey Yang

Open access · bronzeAbstract read
In one paragraph

Article in The Annals of thoracic surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Nicholas R MayneDepartment of Surgery, Duke University, Durham, North Carolina.
Holly ElserStanford School of Medicine, Stanford, California; Division of Epidemiology and Biostatistics, University of California Berkeley School of Public Health, Berkeley, California.
Belle K LinUniversity of Arizona College of Medicine, Phoenix, Arizona.
Vignesh RamanDepartment of Surgery, Duke University, Durham, North Carolina.
Douglas LiouDepartment of Cardiothoracic Surgery, Stanford University, Stanford, California; Stanford Health Care ValleyCare, Stanford, California.
Xiao LiCase Western University, Cleveland, Ohio.
Thomas A D'AmicoDepartment of Surgery, Duke University, Durham, North Carolina.
Chi-Fu Jeffrey YangDepartment of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: cjyang@post.harvard.edu.
Duke University · USCase Western Reserve University · USMassachusetts General Hospital · USStanford Health Care · USStanford Medicine · USUniversity of Arizona · US

Funding

Translational Research in Surgical OncologyT32CA093245 · NCI · DUKE UNIVERSITY · PI ALLEN, PETER J, HARPOLE, DAVID H. · 2002 to 2020
$5.2M
NCI NIH HHS T32 CA093245
6 · The paper itself

Abstract

backgroundDuring the COVID-19 pandemic, patients with lung cancer may experience treatment delays. The objective of this study was to evaluate the impact of extended treatment delays on survival among patients with stage I typical bronchopulmonary carcinoid (BC), lepidic predominant adenocarcinoma (LPA) or invasive adenocarcinoma with a lepidic component (ADL).

methodsUsing National Cancer Database data (2004-2015), multivariable Cox regression analysis with penalized smoothing splines was performed to examine the association between treatment delay and all-cause mortality for stage I BC, LPA, and ADL. Propensity score-matched analyses compared the overall survival of patients who received "early" vs "delayed" surgery (ie, 0-30 vs 90-120 days after diagnosis) across the different histologic subtypes.

resultsDuring the study period, patients with stage I BC (n = 4947), LPA (n = 5340), and ADL (n = 6816) underwent surgery. Cox regression analysis of these cohorts showed a gradual steady increase in the hazard ratio the longer treatment is delayed. However, in propensity score-matched analyses that created cohorts of patients who underwent early and delayed surgery that were well-balanced in patient characteristics, no significant differences in 5-year survival were found between early and delayed surgery for stage I BC (87% [95% CI:77%-93%] vs 89% [95% CI: 80%-94%]), stage I LPA (73% [95% CI: 64%-80%] vs 77% [95% CI: 68%-83%]), and stage I ADL (71% [95% CI: 64%-76%] vs 69% [95% CI: 60%-76%]).

conclusionsDuring the COVID-19 pandemic, for early-stage indolent lung tumors and part-solid ground glass lung nodules, a delay of surgery by 3-4 months after diagnosis can be considered.

Indexed as

AdenocarcinomaAdenocarcinoma of LungCOVID-19Lung NeoplasmsHumansNeoplasm StagingPandemicsRetrospective Studies

Identifiers

PMID34329603
PMCPMC8604629
OpenAlexW3185047720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.